UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE 

SECURITIES EXCHANGE ACT OF 1934

 

For the month of May, 2019

 

Commission File Number: 001-38452

 

MEREO BIOPHARMA GROUP PLC

(Translation of registrant’s name into English)

 

4th Floor, One Cavendish Place,

London, W1G 0QF, United Kingdom

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x  Form 40-F ¨ 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ 

 

 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of PDMR Dealing

 

London, May 22, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on May 20, 2019, Alexandra (“Wills”) Hughes-Wilson, Head of Patient Access & Commercial Planning at Mereo, purchased 1,650 American Depositary Shares (ADSs) at a price of USD5.42 per share.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 

1 Details of the person discharging managerial responsibilities
a) Name Alexandra (“Wills”) Hughes-Wilson
2 Reason for the notification
a) Position/status Head of Patient Access & Commercial Planning, Mereo BioPharma Group plc
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Mereo BioPharma Group plc
b) LEI 213800U8JQHIJOS5AS09
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
b) Nature of the transaction PURCHASE of ADSs

           
c) Price(s) and volume(s)   Price(s) Volume(s)  
      USD5.42 1,650  
           

d) Aggregated information:  volume, Price

Aggregated volume: 1,650

 

Aggregated price: USD5.42

 

e) Date of the transaction 2019-05-20
f) Place of the transaction XNMS    

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: May 22, 2019

 

  MEREO BIOPHARMA GROUP PLC
   
   
   
  By: /s/ Charles Sermon
    Name:   Charles Sermon
    Title:     General Counsel